<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820803</url>
  </required_header>
  <id_info>
    <org_study_id>CPC01</org_study_id>
    <nct_id>NCT04820803</nct_id>
  </id_info>
  <brief_title>Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19</brief_title>
  <official_title>PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rosa Tarrago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dentaid SL</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Sanitaria Aragón</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot, randomized and controlled clinical trial for the evaluation of the decrease in the&#xD;
      viral load of SARS-CoV-2 in the oropharynx in patients with COVID-19 through the use of&#xD;
      mouthwash containing cetylpyridinium chloride (CPC) (0.07%) in mouthwash.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the clinical trial is to determine the short-term efficacy of&#xD;
      cetylpyridinium chloride (CPC) mouthwashes to assess changes in the threshold cycle value of&#xD;
      the analysis of the SARS-CoV-2 oropharyngeal saliva sample, in patients diagnosed with&#xD;
      COVID-19 and with symptomatology compatible with the disease. A randomized double-blind pilot&#xD;
      clinical trial (evaluator and patients) will be developed in patients with a diagnosis of&#xD;
      COVID-19 and symptoms of the disease. The experimental group will perform a single rinse with&#xD;
      a mouthwash containing Cetylpyridinium Chloride (CPC) while the placebo group will perform&#xD;
      the same rinse, but with a harmless liquid that will act as a placebo. The study will be&#xD;
      carried out in the Zaragoza III Health Sector, with patients belonging to the Zaragoza II&#xD;
      Health Sector, collaborating with the &quot;Seminario&quot; health center and the Lozano Blesa Clinical&#xD;
      University Hospital (HCULB). This project will be carried out in accordance with the CONSORT&#xD;
      guidelines for clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 40 subjects in the first group and 40 in the second were required to detect a difference equal to or greater than 5 units. The common standard deviation is assumed to be 10 (12). A loss to follow-up rate of 20% has been estimated.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized double-blind pilot clinical trial (evaluator and patients) in patients with a diagnosis of COVID-19 and symptoms of the disease.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Threshold cycle value of SARS-CoV-2 by Polymerase Chain Reaction (PCR) in saliva samples</measure>
    <time_frame>3 months</time_frame>
    <description>Threshold cycle value of SARS-CoV-2 by Polymerase Chain Reaction (PCR) in saliva samples before antd 2hours after mouthwashes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 Nucleocapsid protein in saliva by ELISA</measure>
    <time_frame>3 months</time_frame>
    <description>Quantitative determination of SARS-CoV-2 Nucleocapsid protein in saliva by ELISA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Cetylpyridinium Chloride (CPC) 0,07%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Distilled water with the same flavor and coloring as the product to be evaluated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients who rinse with distilled water mouthwash for 60 seconds</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE</intervention_name>
    <description>one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds</description>
    <arm_group_label>Cetylpyridinium Chloride (CPC) 0,07%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>one mouthwash containing distilled (placebo) water for 60 seconds</description>
    <arm_group_label>Placebo: Distilled water with the same flavor and coloring as the product to be evaluated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients older than 18 years and younger than 80 years.&#xD;
&#xD;
          -  Patients with a medical indication for a diagnostic test for active infection to&#xD;
             SARS-CoV-2&#xD;
&#xD;
          -  Patients who present mild symptoms typical of COVID-19 and who have less than three&#xD;
             days of evolution&#xD;
&#xD;
          -  Patients who have cognitive and motor skills to perform mouthwash correctly.&#xD;
&#xD;
          -  Patients who understand and speak Spanish&#xD;
&#xD;
          -  Patients who freely give their consent to participate in the study, after a correct&#xD;
             understanding of its objectives and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hospitalization criteria (moderate or severe symptoms)&#xD;
&#xD;
          -  Vulnerable populations such as pregnant, lactating,&#xD;
&#xD;
          -  Patients with recent medical diagnosis (≤ 1 month) of pneumonia&#xD;
&#xD;
          -  Patients with hyposialia&#xD;
&#xD;
          -  Patients with consumption of oral antiseptics (in the form of mouthwash containing&#xD;
             CPC, povidone iodine rinses, alcohol mouthwash and essential oils) and toothpastes&#xD;
             with CPC during the last month.&#xD;
&#xD;
          -  Patients with cognitive impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seminario Health Center and Lozano Blesa University Clinical Hospital</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigación Sanitaria Aragón</investigator_affiliation>
    <investigator_full_name>Rosa Tarrago</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>cetylpyridinium</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>mouthwashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetylpyridinium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

